2010 Fiscal Year Final Research Report
Functional analysis of Angiotensin Receptor Binding Protein in The Cardiovascular Regulation
| Project/Area Number |
20590979
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
TAMURA Kouichi Yokohama City University, 医学部, 准教授 (40285143)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UMEMURA Satoshi 横浜市立大学, 医学研究科, 教授 (00128589)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
ORIUCHI Masatsugu 愛媛大学, 医学研究科, 教授 (40150338)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Keywords | 高血圧学 / 分子心臓血管病態学 |
|---|
| Research Abstract |
We hypothesized that a downregulation of the cardiac ATRAP to angiotensin II type 1 receptor ratio is involved in the pathogenesis of cardiac hypertrophy. To examine this hypothesis, we next generated transgenic mice expressing ATRAP specifically in cardiomyocytes under control of the α-myosin heavy chain promoter. In cardiac-specific ATRAP transgenic mice, the development of cardiac hypertrophy, activation of p38 mitogen-activated protein kinase, and expression of hypertrophy-related genes in the context of angiotensin II treatment were completely suppressed, in spite of there being no significant difference in blood pressure on radiotelemetry between the transgenic mice and littermate control mice. These results demonstrate that cardiomyocyte-specific overexpression of ATRAP in vivo abolishes the cardiac hypertrophy provoked by chronic angiotensin II infusion, thereby suggesting ATRAP to be a novel therapeutic target in cardiac hypertrophy.
|
